Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.23.02398 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Richard T Bryan und 27 weiteren Autor:innen. Beteiligte Einrichtung: Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Magnetic Resonance Imaging, Cystectomy, Multiparametric Magnetic Resonance Imaging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Transurethral resection of bladder tumor (TURBT) is the initial staging procedure for new bladder cancers (BCs). For muscle-invasive bladder cancers (MIBCs), TURBT may delay definitive treatment. We investigated whether definitive treatment can be expedited for MIBC using flexible cystoscopic biopsy and multiparametric magnetic resonance imaging (mpMRI) for initial staging. PATIENTS AND METHODS We conducted a prospective open-label, randomized study conducted within 17 UK hospitals (registered as ISRCTN 35296862). Participants with suspected new BC were randomly assigned 1:1 to TURBT-staged or mpMRI-staged care, with minimization factors of sex, age, and clinician visual assessment of stage. Blinding was not possible. Patients unable/unwilling to undergo mpMRI or with previous BC were ineligible. The study had two stages with separate primary outcomes of feasibility and time to correct treatment (TTCT) for MIBC, respectively. RESULTS Between May 31, 2018, and December 31, 2021, 638 patients were screened, and 143 participants randomly assigned to TURBT (n = 72; 55 males, 15 MIBCs) or initial mpMRI (n = 71; 53 males, 14 MIBCs). For feasibility, 36 of 39 (92% [95% CI, 79 to 98]) participants with suspected MIBC underwent mpMRI. The median TTCT for participants with MIBC was significantly shorter with initial mpMRI (n = 12, 53 days [95% CI, 20 to 89] v n = 14, 98 days [95% CI, 72 to 125] for TURBT, log-rank P .02). There was no detriment for participants with non-MIBC (median TTCT: n = 30, 17 days [95% CI, 8 to 25] for mpMRI v n = 28, 14 days [95% CI, 10 to 29] for TURBT, log-rank P = .67). No serious adverse events were reported. CONCLUSION The mpMRI-directed pathway led to a 45-day reduction in TTCT for MIBC. Incorporating mpMRI ahead of TURBT into the standard pathway was beneficial for all patients with suspected MIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Bladder Cancer Research Centre, Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
- The Translational Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
- Patient Representative, Tetbury, United Kingdom.
- University Hospital Coventry and Warwickshire, Coventry, United Kingdom.
ORCID-Profile: Richard T Bryan, Wenyu Liu, Sarah J Pirrie, Jean Gallagher, Ana I Hughes, Kieran P Jefferson, Harriet P Mintz, Ann M Pope, Gokul Kanda Swamy, David Mak, Amar Mohee, Thiagarajan Nambirajan, James W F Catto, Prashant Patel, Nicholas D James
Zitieren
APA
Bryan, R. T., Liu, W., Pirrie, S. J., Amir, R., Gallagher, J., Hughes, A. I., Jefferson, K. P., Knight, A., Nanton, V., Mintz, H. P., Pope, A. M., Cherian, J., Ekwueme, K., Gommersall, L., Hellawell, G., Hunter-Campbell, P., Kanda Swamy, G., Kotwal, S., Kumar, V., …, & BladderPath Collaborative Group (2025). Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02398
Vancouver
Bryan RT, Liu W, Pirrie SJ, Amir R, Gallagher J, Hughes AI, et al. Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco.23.02398
BibTeX
@article{Bryan2025,
author = {Bryan, Richard T and Liu, Wenyu and Pirrie, Sarah J and Amir, Rashid and Gallagher, Jean and Hughes, Ana I and Jefferson, Kieran P and Knight, Allen and Nanton, Veronica and Mintz, Harriet P and Pope, Ann M and Cherian, Jacob and Ekwueme, Kingsley and Gommersall, Lyndon and Hellawell, Giles and Hunter-Campbell, Paul and Kanda Swamy, Gokul and Kotwal, Sanjeev and Kumar, Vivekanandan and Mak, David and Mohee, Amar and Nambirajan, Thiagarajan and Ward, Douglas G and Kennish, Steven J and Catto, James W F and Patel, Prashant and James, Nicholas D and BladderPath Collaborative Group, BladderPath Collaborative Group},
title = {Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.23.02398}
}
EUVIMED